Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
229 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07840976 | Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL(Ph+ ALL-2026) | not yet recruiting | Phase 2 | 22 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07692529 | A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia | not yet recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 0 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma(CAREMM-010) | not yet recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831395 | Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL(RPLM-RS) | not yet recruiting | Phase 2 | 23 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07652905 | CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia(CAREMM-011) | recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07809594 | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma(GZLTCST0001) | active not recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828522 | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma(CAREMM-009) | not yet recruiting | Phase 2 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07828535 | Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML | not yet recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment(CAREMM-012) | recruiting | Phase 2 | 26 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease(BEYOND-MM 001) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07789522 | Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma(HRMM-001) | not yet recruiting | Phase 2 | 15 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT05495035 | Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | recruiting | Phase 1 | 19 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07648459 | CM336-SOC for Dynamically High-Risk Multiple Myeloma Study(CAREMM-013) | not yet recruiting | Phase 2 | 46 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07757672 | Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 11, 2026 | clinicaltrials |
| NCT06529250 | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML(HADCEBPA2023) | recruiting | N/A | 148 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07131059 | MRD-positive AML Clinical Study | recruiting | N/A | 537 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07188740 | Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia | recruiting | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07495631 | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | recruiting | N/A | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06265545 | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia | recruiting | N/A | 458 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | recruiting | Phase 3 | 284 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07409454 | MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma(CAREMM-007) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07490288 | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | recruiting | N/A | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751471 | BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)(AL-004) | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07725705 | SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 / Phase 2 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT07726160 | A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma(KIV-318) | not yet recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06745687 | BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma | recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol(CCCG-I/HR-ALL) | recruiting | Phase 2 / Phase 3 | 1,800 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07493161 | Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL | recruiting | N/A | 110 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07723911 | A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL | not yet recruiting | Phase 3 | 212 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 23, 2026 | clinicaltrials |
| NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse | not yet recruiting | Phase 3 | 191 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06464185 | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05870917 | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia | active not recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07234110 | CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors | recruiting | N/A | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07644481 | Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07643103 | Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial(Ph- ALL-2026) | not yet recruiting | Phase 2 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT06594640 | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 108 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07555470 | Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma(CUREFL03) | recruiting | Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05850286 | A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities | active not recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06066242 | Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy | active not recruiting | N/A | 113 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06116318 | A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia | withdrawn | — | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06504199 | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma(ZGR) | active not recruiting | Phase 2 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 13, 2026 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials